{
    "nct_id": "NCT05338931",
    "age": "Adults",
    "cancer_center_accrual_goal_upper": 0,
    "curated_on": "2022-04-21",
    "study_start_date": "2022-03-15",
    "study_completion_date": null,
    "data_table4": "Interventional",
    "drug_list": {
        "drug": [
            {
                "drug_name": "Drug: AT101(Anti-CD19 Chimeric Antigen Receptor T cell)"
            }
        ]
    },
    "long_title": "An Open-label, Single-arm, Multi-center, Phase I/II Study to Evaluate the Safety, Tolerability, and Efficacy of AT101 (Anti-CD19 Chimeric Antigen Receptor T Cell) in Patients With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma",
    "last_updated": "2022-05-26",
    "management_group_list": {
        "management_group": [
            {
                "is_primary": "Y",
                "management_group_name": "Group1"
            }
        ]
    },
    "oncology_group_list": {
        "oncology_group": [
            {
                "group_name": "Group1",
                "is_primary": "N"
            }
        ]
    },
    "phase": "PHASE1",
    "principal_investigator": "Deok-hyun Yoon",
    "principal_investigator_institution": "Asan Medical Center, 88, Olympic-ro 43-gil, Songpa-gu, Seoul, South Korea",
    "program_area_list": {
        "program_area": [
            {
                "is_primary": "Y",
                "program_area_name": "Program1"
            }
        ]
    },
    "protocol_id": 0,
    "protocol_ids": [],
    "protocol_no": "",
    "protocol_target_accrual": 82,
    "protocol_type": "INTERVENTIONAL",
    "prior_treatment_requirements": [
        "Inclusion Criteria:",
        "* B cell non-Hodgkin lymphoma based on WHO classification 2017",
        "* incompatible with existing standard therapies or have had disease progression, and whose standard therapies do not currently have available standard therapies due to reasons such as intolerance/inadequacies or rejection",
        "* The Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0 or 1",
        "* adequate hematological, kidney, liver, lung, heart and bone marrow function without blood transfusion within two weeks prior to screening",
        "* Those with a minimum life expectancy of 12 weeks or more",
        "* In women with childbearing, clinical response tests (serum- or ure-hCG) were negatively identified during this trial",
        "* Those who have agreed in writing to participate voluntarily in this trial",
        "Exclude - Exclusion Criteria:",
        "Exclude - * Those who have previously had a history of treating homologic autologous hemoblastitis (allogeneic HSCT)",
        "Exclude - * At101/adcidmilisers, anticancer chemotherapy/adcidms for lymphodeletion or those who are hypersensitive to tocilizumab",
        "Exclude - * Those who cannot take autologous blood",
        "Exclude - * Those who have received chemotherapy or radiotherapy, excluding lymphodeletion, within two weeks prior to IP administration",
        "Exclude - * Persons who have not been recovered (CTCAE grade \u22641 or baseline) due to previous treatment",
        "Exclude - * Those who have identified a condition that, at the test's discretion, may affect safety and validation during the trial period.",
        "Exclude - * Those who have identified the following forces at the time of screening:",
        "Exclude - 1. Those who have been clinically aware of heart disease within 6 months prior to screening",
        "Exclude - 2. Those identified as thromboembolic disease, pulmonary embolism or bleeding bleeding diatheses within 6 months prior to screening",
        "Exclude - 3. Those who have identified a history of malignant tumors other than B-cell non-Hodgkin's lymphoma within five years prior to screening",
        "Exclude - 4. Those who have undergone major surgery within 4 weeks prior to screening",
        "Exclude - 5. Those who have undergone non-critical surgery within two weeks prior to screening",
        "Exclude - * Childbearing women or men who do not have the will to use effective contraception for a longer period of time, either 12 months after clinical trial period and AT101 administration or when AT101 in the body is not identified",
        "Exclude - * Those who have been administered or applied to other IP/ID within 4 weeks of screening",
        "Exclude - * Those who are addicted to alcohol and/or medication",
        "Exclude - * Those who are unfit or unable to participate in this trial when judged by PI"
    ],
    "short_title": "Safety, Tolerability, and Efficacy of AT101 in Patients With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma",
    "site_list": {
        "site": []
    },
    "sponsor_list": {
        "sponsor": [
            {
                "is_principal_sponsor": "Y",
                "sponsor_name": "AbClon",
                "sponsor_protocol_no": "",
                "sponsor_roles": "sponsor"
            }
        ]
    },
    "staff_list": {
        "protocol_staff": []
    },
    "status": "open to accrual",
    "summary": "Determine MTD based on the safety and tolerability of AT101 and the RP2D for patients with recurrent or non-reactive B-cell NHL.",
    "treatment_list": {
        "step": [
            {
                "step_internal_id": 111,
                "step_code": "1",
                "step_type": "Registration",
                "arm": [
                    {
                        "arm_code": "AT101(Anti-CD19 Chimeric Antigen Receptor T cell)",
                        "arm_internal_id": 0,
                        "arm_description": "Anti-CD19 Chimeric Antigen Receptor T cell",
                        "arm_suspended": "N",
                        "dose_level": [
                            {
                                "level_code": "0",
                                "level_description": "Drug: AT101(Anti-CD19 Chimeric Antigen Receptor T cell)",
                                "level_internal_id": 0,
                                "level_suspended": "N"
                            }
                        ]
                    }
                ],
                "match": [
                    {
                        "clinical": {
                            "age_numerical": ">=19",
                            "oncotree_primary_diagnosis": "Lymphoid Neoplasm"
                        }
                    }
                ]
            }
        ]
    }
}